Jonathan Perez Deane serves as the Senior Director and Head of Biology at Trotana Therapeutics, where he leverages over 15 years of extensive experience in drug discovery to drive innovative solutions in immunology and cancer biology. At Trotana, a seed-stage startup, Jonathan leads a dynamic...
Jonathan Perez Deane serves as the Senior Director and Head of Biology at Trotana Therapeutics, where he leverages over 15 years of extensive experience in drug discovery to drive innovative solutions in immunology and cancer biology. At Trotana, a seed-stage startup, Jonathan leads a dynamic team of biologists dedicated to advancing the understanding of signal transduction pathways and their implications in disease treatment. His leadership is pivotal in orchestrating a variety of key projects that encompass biochemical and screening assays, cellular biology, and bioinformatics, all aimed at translating basic scientific findings into viable therapeutic strategies.
Jonathan's expertise in genomics and molecular biology is instrumental in the development of cutting-edge in vitro models that facilitate the identification of novel drug candidates. His proficiency in techniques such as flow cytometry, ELISA, and qPCR enables the team to conduct rigorous analysis and validation of biological hypotheses, ensuring that each project is grounded in robust scientific evidence. Under his guidance, Trotana Therapeutics is not only focused on discovering new treatments but is also committed to fostering a culture of collaboration and innovation, where every team member contributes to the overarching goal of curing diseases.
With a passion for bridging the gap between basic research and clinical application, Jonathan is dedicated to enhancing the pipeline of therapeutic options available to patients. His vision for Trotana Therapeutics is to harness the power of cutting-edge science to develop transformative therapies that can significantly improve patient outcomes in the fields of immunology and oncology.
